Neuroone Medical Technologies is trading 5.42% down now at $1.57, and no new company-specific announcement was identified for September 4, 2026.
- The latest major catalyst remains the August 13 fiscal Q3 report, which showed $2.0 million in product revenue but included constrained fiscal-year revenue guidance tied to shipment timing and manufacturing capacity.
- The decline is occurring despite a modestly positive Nasdaq; no clear market-wide explanation is established.
- Monitoring is warranted for delayed filings or company news.